Shares of NLS Pharmaceutics Ltd. (NASDAQ:NCEL – Get Free Report) traded down 0.8% on Wednesday . The stock traded as low as $2.50 and last traded at $2.50. 10,790 shares were traded during mid-day trading, a decline of 41% from the average session volume of 18,316 shares. The stock had previously closed at $2.52.
NLS Pharmaceutics Price Performance
The business’s fifty day moving average price is $2.58 and its 200 day moving average price is $5.14.
NLS Pharmaceutics Company Profile
NLS Pharmaceutics (NASDAQ: NCEL) is a clinical-stage biopharmaceutical company headquartered in Zurich, Switzerland, with additional operations in the United States. The company focuses on the development of small-molecule therapies designed to address disorders of the circadian rhythm and sleep-wake cycle. It leverages proprietary controlled-release and receptor-targeting approaches to optimize drug exposure over a 24-hour period.
The core of NLS Pharmaceutics’ pipeline consists of novel melatonin receptor agonists aimed at treating rare and orphan sleep disorders such as non-24-hour sleep-wake disorder and idiopathic hypersomnia.
Featured Articles
Receive News & Ratings for NLS Pharmaceutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NLS Pharmaceutics and related companies with MarketBeat.com's FREE daily email newsletter.
